Boston, United States
Overview: Xeno Therapeutics, a not-for-profit, clinical-stage regenerative medicine company, is dedicated to advancing xenotransplantation to therapeutic reality. They are focused on developing innovative cell and tissue-based research solutions and have gained FDA acceptance for their pathogen screening and validated assays, providing a strong regulatory pathway for the clinical advancement of xenogeneic cells, tissues, and organs.
Offerings: The company accelerates the development, testing, training, and commercialization of live biotherapeutic products, aiming to deliver on the promise of regenerative medicine.
Founded: 2016
Industries: Biotechnology
Headquarter: United States
Last Investment: Not Available
Xeno Therapeutics' commitment to developing solutions in regenerative medicine, particularly in the field of xenotransplantation, holds promise for the future of organ and tissue transplantation. Their focus on leveraging innovative technologies and their robust regulatory pathway makes them a compelling player in the biotechnology industry, with potential for significant impact.
